ALLOBLAST® – Allogeneic Fibroblast Derived from Foreskin

ALLOBLAST® belongs to the Tissue Biotechnology Stem Cell, Biobank and Tissue Engineering Center and is the first registered allogeneic fibroblast cell product in Turkey.

ALLOBLAST® is an allogeneic application method based on multiplying fibroblast cells obtained from newborn foreskin with bioengineering techniques in a high-tech laboratory environment and injecting them into the area needed by the person. ALLOBLAST® is an allogeneic fibroblast product developed and put into use for the first time in Turkey by scientists at DOKU BIOTECHNOLOGY Stem Cell, Biobank and Tissue Engineering Center.

ALLOBLAST ® is not a stem cell product. Stem cells have descriptive names such as mesenchymal stem cell, hematopoietic stem cell, embryonic stem cell. Today, stem cells used experimentally for tissue regeneration and treatment of metabolic diseases are known as “mesenchymal stem cells”. The production of mesenchymal stem cells requires a GMP laboratory approved by the Ministry of Health and a production process of at least 4-6 weeks (for autologous products). Apart from this, products that are promoted, applied and claimed to be stem cells unfortunately cannot be accepted as stem cells. In addition, these products do not have quality analyzes. In cellular applications; the preparation of a special product for you using your own cell or tissue does not mean that it is reliable or effective! Even your own tissues must be processed and produced in “tissue/cell processing authorized facilities”, i.e. GMP-approved laboratories, undergo quality analyses and be given to you for application after being approved for compliance with national and international quality standards.

ALLOBLAST (Allogeneic Fibroblast) is a registered trademark presented for the first time in Turkey by DOKU BIOTECHNOLOGY STEM CELL, BIONBANK AND TISSUE ENGINEERING and is introduced to physicians with the solution partnership of GENESİS BIOMEDICAL INC. Some copy, imitation, etc. products offered in the market as allogeneic fibroblasts have nothing to do with the brands/products offered by our organization or our solution partners.

ALLLOBLAST® Where is the Product Obtained? What is its Reliability?

ALLOBLAST® is derived from the foreskins of newborn boys. On average, one in every 500 foreskins can be considered to fulfill the criteria to be a healthy donor. For this reason, not every newborn is considered a suitable donor for ALLOBLAST production. In addition, thanks to the high-tech production techniques of our center, ALLOBLAST can be produced for 1000s of people from the foreskin of only 1 suitable donor. Before the reliability of the ALLOBLAST source is confirmed, clinical product production processes are not started and the tissues are destroyed. Records are kept for sharing with the Ministry of Health.

  • All evaluations and safety studies are based on EMA (European Medicines Agency) and FDA (US Food and Drug Administration) donor criteria, with additional analyses performed by our center. This process proceeds in line with the permission of the Ministry of Health and the authorization given to our center.
    Informed consent is obtained from the family donating the foreskin to our center and the doctor performing the procedure.
  • Follow-up is performed from the last 4 months of pregnancy until the first 3 days after the birth of the baby.
  • Twenty-one different parameters, including the mother and father, are examined to ensure that there is no risk for the donor.
  • The past history of the mother and father is evaluated.
  • Sterility, Serology and PCR tests are performed and it is documented that it is clean in terms of infections such as viruses, bacteria, fungi, etc. and it is recorded to be stored in our center and shared with the Ministry of Health.
  • The foreskin is tested to ensure the production of sufficient quality and number of ALLOBLAST.
  • Alloblast cells are produced and banked on an industrial scale with specific, validated techniques and GMP grade components, taking into account allogeneic use, not in line with standard cord blood banking systems.

ALLOBLAST in 3 steps

By making an examination appointment with your doctor, you will be interviewed about your aesthetic / cosmetic purpose or any dermatological problem and a decision will be made together with your physician in line with your suitability for ALLOBLAST application.

Prior to ALLOBLAST ® applications, the Cellular Product Order Form and Informed Consent Form are read, any unclear issues are investigated, detailed information is obtained from the physician, and the product order is sent to our center through your physician. At least one day before the day the application is planned to be performed, the order is sent to our center via Whatsapp, Mobile Call or e-mail. In our facility, which has received GMP, Human Tissue and Cell Product Production and Banking approvals from the Ministry of Health, the required amount of billions of allogeneic fibroblast cells cryopreserved in a high-tech nitrogen tank are taken and prepared sterile for you. This process goes through the quality control processes specified by the Ministry of Health and the European Standard, which are specific to the ALLOBLAST production technique.

The person comes to the clinic; the skin is numbed with topical anesthetic creams. ALLOBLAST® 27G-30G is drawn into sterile syringes and injected into the required area. ALLOBLAST® application consists of a single session. If additional sessions are requested in the same area, a break of at least 3 weeks should be taken.
*After the application of ALLOBLAST, while the skin shines, brightens and looks lively, improvement in fine lines and color tone differences, increase in moisture capacity at the end of the 1st month, a noticeable reduction in skin wrinkles, skin tightening and tightening against gravity can be observed at the end of the 3rd month. It has been shown in scientific and clinical studies that the effect can last for at least 1 year and up to 5 years.

* Expressed in line with the feedback of 500+ doctors and 500+ people who had the application.

ALLOBLAST® Benefits

  • It consists of pure newborn fibroblast cells that are healthy, young and resistant to adverse metabolic stresses.

    (1) Expressed in comparison to autologous fibroblasts based on laboratory tests.
    (2) Neonatal fibroblasts do not elicit immune responses when they are obtained from specific donors (selection), at specific stages and can be produced under specific production and quality criteria.
    (3) Pure neonatal fibroblasts contain bioactive molecules produced by the cells and isotonic saline as a carrier.

  • It is one of the cellular treatment methods approved by the FDA and EMA (European Medicines Agency) in the world.

  • Collagen production is 4 times higher than fibroblasts in their 40s.(1)
    Permanent and longer regenerative effect is targeted thanks to long telomeres.

  • It is produced in a GMP approved stem cell, biobank and tissue engineering center with the permission of the Ministry of Health and is tested and approved.

  • It can be applied to dermal areas all over the body, including around the eyes and genital area.

  • It can be applied the next day only if requested 24 hours in advance (same day for Ankara).

  • The recommended application is a single session, but multiple sessions can also be performed with the doctor’s approval.

  • There is no need for serology tests, biopsy and blood sampling, so no time is lost with production processes that take at least 4 weeks.

  • Does not cause allergy or immune reaction. (2)

  • It does not contain Botox or any filler components, it is a pure cell solution. (3)

  • It does not produce an appearance that may cause changes in mimicry or facial expression.

ALLOBLAST ® Uygulamasının Kullanım Alanları

  • Supporting the removal of wrinkles on the skin,
  • Supporting the lightening of blemishes and dark areas,
  • Supporting the closure of chronic wounds that do not close (diabetes, compression, venous ulcers, etc.),
  • Supporting facial rejuvenation applications that can be done with mesotherapy,
  • Supporting the filling of pits (atrophic scars) after conditions such as acne or chickenpox,
  • Supporting the treatment of cavities and scarring due to burns, previous surgery or trauma,
  • Supporting the stimulation of hair follicles in cases of baldness,
  • There are scientific or clinical studies showing that it can be used in dentistry to support the prevention of gum recession.

ALLOBLAST is an application based on increasing the concentration of fibroblasts that produce extracellular matrix proteins known to be effective in dermal regeneration, especially collagen and elastin, by placing them on the skin. However, it should be known that the person’s condition, age, genetic predispositions, lifestyle, food consumption habits and many other factors will affect the success of this application and the application decision should be made after a doctor’s evaluation.

All of the information on the website is for informational purposes. In addition to the explanations, a reference list of scientific and clinical studies is included on the pages. The use of any product or products is decided by the person who wants to have cellular application and the doctor who will perform the application.

Doku Biotechnology Stem Cell, Biobank and Tissue Engineering Center, as a facility authorized by the Ministry of Health and having permission documents in this context, is obliged to produce cellular products in accordance with national/international norms and GMP requirements, to perform quality analyzes, to store and to deliver the cellular product to the doctor who requests and consents to perform the application for the recipient. The application process must be performed by the physician under appropriate clinical conditions, with the technique and duration appropriate to the indication based on scientific and clinical data in the world, within the framework of the law and professional ethical rules.

Scientific Research

  1. Mehrabani D, Manafi N. Role of Cultured Skin Fibroblasts in Aesthetic and Plastic Surgery. World J Plast Surg. 2013;2(1): 2-5.
  2. Weiss, R.A. Autologous cell therapy: Will it replace dermal fillers? Fac. Plast. Surg. Clin.N. Am. 2013, 21, 299–304.
  3. Morimoto, N.; Saso, Y.; Tomihata, K.; Taira, T.; Takahashi, Y.; Ohta, M.; Suzuki, S. Viability and function of autologous and allogeneic fibroblasts seeded in dermal substitutes after implantation. J. Surg. Res. 2005, 125, 56–67.
  4. Smith, S.R.; Munavalli, G.; Weiss, R.; Maslowski, J.M.; Hennegan, K.P.; Novak, J.M.A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles. Dermatol. Surg. 2012, 38, 1234–1243.
  5. Wisser, D.; Steffes, J. Skin replacement with a collagen based dermal substitute, autologous keratinocytes and fibroblasts in burn trauma. Burns 2003, 29, 375–380.
  6. Boss, W.K., Jr.; Usal, H.; Fodor, P.B.; Chernoff, G. Autologous cultured fibroblasts: A protein repair system. Ann. Plast. Surg. 2000, 44, 536–542.
  7. Watson, D.; Keller, G.S.; Lacombe, V.; Fodor, P.B.; Rawnsley, J.; Lask, G.P. Autologous fibroblasts for treatment of facial rhytids and dermal depressions. A pilot study. Arch. Fac. Plast. Surg. 1999, 1, 165–170.
  8. Weiss, R.A.; Weiss, M.A.; Beasley, K.L.; Munavalli, G. Autologous cultured fibroblast injection for facial contour deformities: A prospective, placebo-controlled, Phase III clinical trial.Dermatol. Surg. 2007, 33, 263–268.
  9. Munavalli, G.S.; Smith, S.; Maslowski, J.M.; Weiss, R.A. Successful treatment of depressed,distensible acne scars using autologous fibroblasts: A multi-site, prospective, double blind, placebo-controlled clinical trial. Dermatol. Surg. 2013, 39, 1226–1236.
  10. Eca, L.P.; Pinto, D.G.; de Pinho, A.M.; Mazzetti, M.P.; Odo, M.E. Autologous fibroblast culture in the repair of aging skin. Dermatol. Surg. 2012, 38, 180–184.
  11. Zhang, X.; Deng, Z.; Wang, H.; Yang, Z.; Guo, W.; Li, Y.; Ma, D.; Yu, C.; Zhang, Y.; Jin, Y.Expansion and delivery of human fibroblasts on micronized acellular dermal matrix for skin regeneration. Biomaterials 2009, 30, 2666–2674.
  12. Boss WK Jr, Usal H, Fodor PB, Chernoff G. Autologous cultured fibroblasts: a protein repair system. Ann Plast Surg 2000 May;44:536–42.
  13. Robert A. Weiss; Margaret A. Weiss; Karen L. Beasley; Girish Munavalli. Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial, 2007 Dermatol Surg 2007;33:263–268.
  14. 2. Wong T, McGrath JA, Navsaria H. The role of fibroblasts in tissue engineering and regeneration. Br J Dermatol 2007; 156:1149-1155.
  15. Solakoglu S, Tiryaki T, Ciloglu SE. The effect of cultured autologous fibroblasts on longevity of cross-linked hyaluronic acid used as a filler. Aesthetic Surg J 2008; 28: 412-416.
  16. Nilforoushzadeh MA, Siadat AH, Arianrad M, Moulavi F, Baradaran EH, Esfahani MHN. Soft tissue augmentation by autologous cultured fibroblasts transplantation for treatment of wrinkles and scars: a case series of 20 patients. J Res Med Sci 2010; 15: 167-171.
  17. Eça LP, Pinto DG, De Pinho AMS, Mazzetti MPV, Odo MEY. Autologous fibroblast culture in the repair of aging skin. Dermatol Surg 2012; 38: 180-184.
  18. Bassetto F, Turra G, Salmaso R, Lancerotto, Del Vecchio DA. Autologous injectable dermis: a clinical and histological study. Plast Reconstr Surg 2013; 131: 589-596
  19. Ferguson PC, Boynton EL, Wunder JS, Hill RP, O’Sullivan B, Sandhu JS, Bell RS. Intradermal injection of autologous dermal fibroblasts improves wound healing in irradiated skin. J Surg Res 1999; 85: 331-338.
  20. Karchilaki I, Topakas G, Castana O, Sotiriou P, Michelakis D, Giokas CS. The use of cultured autologous fibroblasts in burn wounds healing process. Burns 2007; 33: 791-792.
  21. Kim JE, Lee OS, Choi J, Son SW, Oh CH. The efficacy of stereoimage optical topometry to evaluate depressed acne scar treatment using cultured autologous fibroblast injection. Dermatol Surg. 2011; 37:1304-13.
  22. Mc Guire MK, Scheyer ET: A randomized, double-blind, placebo controlled study to determine the safety and efficacy of cultured and expanded autologous fibroblast injections for the treatment of interdental papillary insufficiency associated with the papilla priming procedure. J Periodontol 2007;78:4-17.
  23. Nolte SV, Xu W, Rennakampff HO, Rodemann HP: Diversity of fibroblasts a review on implications for skin tissue engineering. Cells Tissue Organs 2008;187:165-76.